Are Analysts Bullish about Johnson & Johnson (NYSE:JNJ) after last week?

Johnson & Johnson (NYSE:JNJ) Logo
Investors sentiment decreased to 0.84 in 2019 Q1. Its down 0.02, from 0.86 in 2018Q4. It is negative, as 57 investors sold Johnson & Johnson shares while 837 reduced holdings. 129 funds opened positions while 620 raised stakes. 1.84 billion shares or 2.89% more from 1.79 billion shares in 2018Q4 were reported.
Federated Investors Inc Pa invested in 605,050 shares or 0.21% of the stock. Horizon Inv Services Ltd reported 0.18% stake. Natl Pension Service invested in 2.46 million shares or 1.32% of the stock. Los Angeles Cap Management Equity invested in 0.99% or 1.27M shares. Mcdaniel Terry holds 177,322 shares. Foster Dykema Cabot And Ma invested 0.37% in Johnson & Johnson (NYSE:JNJ). Caprock Gp Inc Inc accumulated 1.02% or 37,617 shares. Great Lakes Advisors stated it has 0.32% in Johnson & Johnson (NYSE:JNJ). Bell Bancshares stated it has 3,392 shares. Rmb Mgmt Lc holds 0.21% in Johnson & Johnson (NYSE:JNJ) or 58,943 shares. Bp Public Limited Com reported 278,000 shares. Primecap Mgmt Communications Ca reported 0% in Johnson & Johnson (NYSE:JNJ). Alps Advisors has invested 0.27% of its portfolio in Johnson & Johnson (NYSE:JNJ). Motley Fool Asset Management Limited Liability Company owns 43,387 shares or 0.7% of their US portfolio. Bowling Portfolio Lc has invested 0.67% of its portfolio in Johnson & Johnson (NYSE:JNJ).

Since June 11, 2019, it had 1 insider purchase, and 0 insider sales for $419,040 activity.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 5 analysts covering Johnson & Johnson (NYSE:JNJ), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Johnson & Johnson has $157 highest and $140 lowest target. $148.80’s average target is 13.44% above currents $131.17 stock price. Johnson & Johnson had 13 analyst reports since March 15, 2019 according to SRatingsIntel. The company was maintained on Wednesday, April 17 by Raymond James. The rating was maintained by Credit Suisse with “Outperform” on Thursday, May 16. The firm has “Buy” rating given on Monday, March 25 by Raymond James. Morgan Stanley maintained the shares of JNJ in report on Tuesday, August 27 with “Equal-Weight” rating. The stock has “Hold” rating by Barclays Capital on Friday, June 21. Morgan Stanley maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, April 17. Morgan Stanley has “Equal-Weight” rating and $145 target. The rating was maintained by Credit Suisse with “Outperform” on Wednesday, April 17. Raymond James maintained the stock with “Outperform” rating in Wednesday, July 17 report. BMO Capital Markets maintained the shares of JNJ in report on Wednesday, April 17 with “Outperform” rating. Below is a list of Johnson & Johnson (NYSE:JNJ) latest ratings and price target changes.

27/08/2019 Broker: Morgan Stanley Rating: Equal-Weight New Target: $145.0000 Maintain
17/07/2019 Broker: Raymond James Rating: Outperform Old Target: $147.0000 New Target: $146.0000 Maintain
12/07/2019 Broker: Credit Suisse Rating: Outperform New Target: $156.0000 Initiates Coverage On
21/06/2019 Broker: Barclays Capital Rating: Hold New Target: $140 Initiate
16/05/2019 Broker: Credit Suisse Rating: Outperform Old Target: $152.0000 New Target: $156.0000 Maintain
03/05/2019 Broker: BidaskScore Rating: Buy Upgrade
17/04/2019 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $154 New Target: $157 Maintain
17/04/2019 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $151 New Target: $152 Maintain
17/04/2019 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $134 New Target: $145 Maintain
17/04/2019 Broker: Raymond James Old Rating: Outperform New Rating: Outperform Old Target: $145 New Target: $147 Maintain

The stock increased 1.25% or $1.62 during the last trading session, reaching $131.17. About 5.89 million shares traded. Johnson & Johnson (NYSE:JNJ) has declined 1.48% since September 11, 2018 and is downtrending. It has underperformed by 1.48% the S&P500.

Johnson & Johnson, together with its subsidiaries, researches and develops, makes, and sells various products in the health care field worldwide. The company has market cap of $346.58 billion. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices. It has a 21.79 P/E ratio. The Consumer segment offers baby care products under the JOHNSONÂ’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSONÂ’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Fool.com which released: “Forget Coca-Cola: Here Are 2 Better Dividend Stocks – Motley Fool” on September 04, 2019, also Finance.Yahoo.com with their article: “How Will Johnson & Johnson’s Opioid Case Ruling Impact Big Pharma Stocks? – Yahoo Finance” published on September 05, 2019, Finance.Yahoo.com published: “10 Healthcare Stocks to Buy Despite the Headlines – Yahoo Finance” on September 10, 2019. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Investorplace.com and their article: “It’s Time to Short Johnson & Johnson Stock – Investorplace.com” published on August 30, 2019 as well as Investorplace.com‘s news article titled: “Johnson & Johnson Stock Is a Gamble, but an Interesting One – Investorplace.com” with publication date: August 21, 2019.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.